101 related articles for article (PubMed ID: 20116114)
1. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings.
Janssen MH; Ollers MC; van Stiphout RG; Buijsen J; van den Bogaard J; de Ruysscher D; Lambin P; Lammering G
Radiother Oncol; 2010 Feb; 94(2):151-5. PubMed ID: 20116114
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
Goldberg N; Kundel Y; Purim O; Bernstine H; Gordon N; Morgenstern S; Idelevich E; Wasserberg N; Sulkes A; Groshar D; Brenner B
Radiat Oncol; 2012 Aug; 7():124. PubMed ID: 22853868
[TBL] [Abstract][Full Text] [Related]
3. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
Vliegen RF; Beets-Tan RG; Vanhauten B; Driessen A; Oellers M; Kessels AG; Arens A; Beets GL; Buijsen J; van Baardwijk A; de Ruysscher D; Lammering G
Strahlenther Onkol; 2008 Sep; 184(9):457-64. PubMed ID: 19016024
[TBL] [Abstract][Full Text] [Related]
4. Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer.
van den Bogaard J; Janssen MH; Janssens G; Buijsen J; Reniers B; Lambin P; Lammering G; Ollers MC
Radiother Oncol; 2011 May; 99(2):137-41. PubMed ID: 21571386
[TBL] [Abstract][Full Text] [Related]
5. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
[TBL] [Abstract][Full Text] [Related]
8. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging.
Janssen MH; Ollers MC; Riedl RG; van den Bogaard J; Buijsen J; van Stiphout RG; Aerts HJ; Lambin P; Lammering G
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):392-9. PubMed ID: 19646825
[TBL] [Abstract][Full Text] [Related]
9. Repeated positron emission tomography-computed tomography and perfusion-computed tomography imaging in rectal cancer: fluorodeoxyglucose uptake corresponds with tumor perfusion.
Janssen MH; Aerts HJ; Buijsen J; Lambin P; Lammering G; Öllers MC
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):849-55. PubMed ID: 21392896
[TBL] [Abstract][Full Text] [Related]
10. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls.
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Vandecaveye V; Stroobants S; Ectors N; Penninckx F; Haustermans K
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):782-90. PubMed ID: 19289265
[TBL] [Abstract][Full Text] [Related]
11. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.
Cascini GL; Avallone A; Delrio P; Guida C; Tatangelo F; Marone P; Aloj L; De Martinis F; Comella P; Parisi V; Lastoria S
J Nucl Med; 2006 Aug; 47(8):1241-8. PubMed ID: 16883000
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.
Freedman GM; Meropol NJ; Sigurdson ER; Hoffman J; Callahan E; Price R; Cheng J; Cohen S; Lewis N; Watkins-Bruner D; Rogatko A; Konski A
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1389-93. PubMed ID: 17394942
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.
Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
[TBL] [Abstract][Full Text] [Related]
16. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings.
Janssen MH; Aerts HJ; Kierkels RG; Backes WH; Ollers MC; Buijsen J; Lambin P; Lammering G
Radiother Oncol; 2010 Feb; 94(2):156-60. PubMed ID: 20080311
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.
Calvo FA; Domper M; Matute R; Martínez-Lázaro R; Arranz JA; Desco M; Alvarez E; Carreras JL
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):528-35. PubMed ID: 14751524
[TBL] [Abstract][Full Text] [Related]
18. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography.
Guillem JG; Puig-La Calle J; Akhurst T; Tickoo S; Ruo L; Minsky BD; Gollub MJ; Klimstra DS; Mazumdar M; Paty PB; Macapinlac H; Yeung H; Saltz L; Finn RD; Erdi Y; Humm J; Cohen AM; Larson S
Dis Colon Rectum; 2000 Jan; 43(1):18-24. PubMed ID: 10813118
[TBL] [Abstract][Full Text] [Related]
20. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
